Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investor page, and a replay will be available for 30 days post-event. The company's management will discuss key developments and insights related to their kidney disease therapeutics pipeline.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +8.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.
A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
| Contact: | |
| Investors: 888-969-7879 IR@travere.com | Media: 888-969-7879 mediarelations@travere.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.